Skip to main content

Search Articles

Found 3,009 articles

  • A Recruiter’s Guide to Hiring a Clinical Research

    A Recruiter’s Guide to Hiring a Clinical Research Associate (CRA)

    • 15 Mar 2024
    • Lucy Walters

    In this guide, we explore the essential steps and considerations for you to keep in mind when searching for a Clinical Research Associate (CRA). From understanding the unique demands of the role to identifying key competencies and conducting effective interviews, this guide will provide you with valuable tips to help you focus your candidate search and engage top talent.

  • Invest in Equality, Diversity and Inclusion, urge

    Invest in Equality, Diversity and Inclusion, urge health leaders

    • 14 Mar 2024
    • Editor

    Health leaders believe investing in equality, diversity and inclusion (EDI) roles is key to improving the NHS.

  • About Amolyt Pharma

    About Amolyt Pharma

    • 14 Mar 2024
    • Editor

    Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.

  • Takeda Announces Positive Topline Results from Pha

    Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

    • 14 Mar 2024
    • Editor

    Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP).

  • AstraZeneca to acquire Amolyt Pharma, expanding la

    AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline

    • 14 Mar 2024
    • Editor

    AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.

  • New AI model detects ninety percent of lymphatic c

    New AI model detects ninety percent of lymphatic cancer cases

    • 14 Mar 2024
    • PharmiWeb Editor

    Medical image analysis using AI has developed rapidly in recent years. Now, one of the largest studies to date has been carried out using AI-assisted image analysis of lymphoma, cancer of the lymphatic system. Researchers at Chalmers University of Technology in Sweden, have developed a computer model that can successfully find signs of lymph node cancer in 90 percent of cases.

  • About Recursion

    About Recursion

    • 13 Mar 2024
    • Editor

    Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets.

  • What do Clinical Research Organisations Do?

    What do Clinical Research Organisations Do?

    • 13 Mar 2024
    • Lucy Walters

    Clinical Research Organisations (CROs) play a crucial role in advancing medical knowledge and therapeutic innovations. As vital intermediaries between pharmaceutical and biotechnology companies, healthcare professionals, and regulatory bodies, CROs help facilitate the clinical development of new drugs, devices, and treatments.

  • Merck Announces Plans to Conduct Clinical Trials o

    Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL ® 9

    • 13 Mar 2024
    • Editor

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types.

  • New Data to be Presented for BioMarin's VOXZOGO® (

    New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

    • 13 Mar 2024
    • Editor

    BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO® (vosoritide) in children with hypochondroplasia, will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024.

  • Jazz Pharmaceuticals to Host Virtual Zanidatamab R

    Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

    • 13 Mar 2024
    • Editor

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m. ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers.

  • High School Seniors Win $1.8 Million at Regeneron

    High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

    • 13 Mar 2024
    • Editor

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Achyuta Rajaram, 17, of Exeter, NH, won the top award in the Regeneron Science Talent Search (STS) 2024, America’s oldest and most prestigious science and math competition for high school seniors.

  • About Metafora Biosystems

    About Metafora Biosystems

    • 12 Mar 2024
    • Editor

    Metafora Biosystems is a healthtech company developing a platform for single-cell metabolism monitoring. METAglut1™ is its first diagnostic test. Metafora’s technology enables medical professionals to measure changes in single-cell metabolism and determine ‘cell metabolic fitness’ or lack thereof, which is a telltale sign of disease, especially in neurology, cancer and inflammatory diseases.

  • Bristol Myers Squibb today announced the appointme

    Bristol Myers Squibb announces the appointment of Guy Oliver as General Manager for the UK and Ireland

    • 12 Mar 2024
    • PharmiWeb Editor

    Bristol Myers Squibb today announced the appointment of Guy Oliver as General Manager for the company in the UK and Ireland.

  • 6 Clinical Research Associate Interview Tips: How

    6 Clinical Research Associate Interview Tips: How to Make a Great Impression

    • 12 Mar 2024
    • Editor

    Your job interview is the perfect opportunity to make a lasting impression on a potential employer. Everything you do before, during, and after your job interview can significantly impact your interviewer’s perception of you.

  • About Cresset

    About Cresset

    • 11 Mar 2024
    • Editor

    Chemists in the world’s leading research organizations use Cresset solutions to discover, design, optimize, synthesize, and track the best small molecules. Our patented CADD Software, collaborative Torx® DMTA design-make-test-analyze platform, and expert Discovery CRO scientists, enable chemists to enhance efficiency and win the race to scientific success in industry sectors including: pharmaceuticals, agrochemicals, fine chemicals and flavors ,and fragrances.

  • More than two-thirds of people with atopic dermati

    More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

    • 11 Mar 2024
    • Editor

    Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema.

  • Wegovy® approved in the US for cardiovascular risk

    Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease

    • 11 Mar 2024
    • Editor

    Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy® based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD).

  • New Phase 2b results for amlitelimab support poten

    New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

    • 11 Mar 2024
    • Editor

    Positive results from Part 2 of the investigational amlitelimab Phase 2b study STREAM-AD showed sustained improvement of signs and symptoms for 28 weeks in adults with moderate to severe AD who previously responded to amlitelimab and continued treatment.

  • About MorphoSys

    About MorphoSys

    • 8 Mar 2024
    • Editor

    At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated.